1. Petersen S.L. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning // Dan. Med. Bull. 2007. Vol. 54. P. 112–139.
2. Champlin R. et al. Allogeneic hematopoietic transplantation as adoptive immunotherapy induction of graft-versus-malignancy as primary therapy // Hematol. Oncol. Clin. 1999. Vol. 13. P. 1041–1053.
3. Schetelig J. et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the cooperative German Transplant Study Group // J. Clin. Oncol. 2003. Vol. 21. P. 2747–2753.
4. Michallet M. et al. Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: 17 cases. Report from the EBMTG // Bone Marrow Transplant. 1991. Vol. 7. P. 275–279.
5. Bandini G. et al. Bone marrow transplantation for chronic lymphocytic leukemia // Bone Marrow Transplantation. 1991. Vol. 7, N 4. P. 251–253.
6. Pavletic Z.P. et al. Bone marrow transplantation in chronic lymphocytic leukemia and lymphomas // Biomed. Pharmacother. 1996. Vol. 50. P. 118–124.
7. Khouri I., Giralt S., Champlin R. Non-myeloablative allogeneic hematopoietic transplantation and induction of graft-versus-malignancy // Cancer Treat. Res. 2002. Vol. 110. P. 137–147.
8. Slavin S. et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases // Blood. 1998. Vol. 91. P. 756–763.
9. Giralt S. et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy // Blood. 1997. Vol. 89. P. 4531–4536.
10. Gratwohl A. et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies // Bone Marrow Transplant. 2009. Vol. 43. P. 275–291.
11. Passweg J.R. et al. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus // Bone Marrow Transplant. 2020. Vol. 55. P. 1604–1613.
12. Khouri I.F. et al. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD // Blood. 2014. Vol. 124. P. 2306–2312.
13. Dreger P. et al. Indication for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus // Leukemia. 2007. Vol. 21. P. 12–17.
14. Rizouli V., Gribben J.G. Role of autologous stem cell transplantation in chronic lymphocytic leukemia // Curr. Opin. Hematol. 2003. Vol. 10. P. 306–311.
15. Reljic T. et al. High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia. A systemic review // Bone Marrow Transplant. 2015. Vol. 50. P. 1069–1074.
16. Rabinowe S.N. et al. Autologous and allogeic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia // Blood. 1993. Vol. 82. P. 1366–1376.
17. Dyer M.J. et al. In vivo purging of residual disease in CLL with Campath-1H // Br. J. Hematol. 1997. Vol. 97. P. 669–672.
18. Passweg J.R.; for the European Society for Blood and Marrow Transplantation (EBMT). The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies // Bone Marrow Transplant. 2019. Vol. 54. P. 1575–1585.
19. Dreger P. et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies // Blood. 2018. Vol. 132. P. 892–902.
20. Schetelig J. et al. Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation // Bone Marrow Transplant. 2017. Vol. 52. P. 552–560.
21. O’Brien SM et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience // Blood. 2018. Vol. 131. P. 1910–1919.
22. Gribben J.G. How and when I do allogeneic transplant in CLL // Blood. 2018. Vol. 132. P. 31–39.
23. Brown J.R. et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia // Biol. Blood Marrow Transplant. 2006. Vol. 12. P. 1056–1064.
24. van Gelder M. et al. Baseline characteristics predicting very good outcome of allogeneic hematopoietic cell transplantation in young patients with high cytogenetic risk chronic lymphocytic leukemia – a retrospective analysis from the Chronic Malignancies Working Party of the EBMT // Clin. Lymphoma Myeloma Leuk. 2017. Vol. 17. P. 667–675.
25. Dreger P. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties // Bone Marrow Transplant. 2019. Vol. 54, N 1. P. 44–52.
26. Roeker L.E. et al. Allogeneic stem cell transplantation (alloHSCT) for chronic lymphocytic leukemia (CLL) in the era of novel agents // Blood. 2019. Vol. 134, suppl. 1. P. 3321.
27. Dreger P. et al. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial // Blood. 2013. Vol. 121. P. 3284–3288.
28. Roberts A.W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2016. Vol. 374. P. 311–322.
29. Sorror M. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT // Blood. 2005. Vol. 106. P. 2912–2919.